These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26206268)

  • 61. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women.
    Petäjä T; Pedersen C; Poder A; Strauss G; Catteau G; Thomas F; Lehtinen M; Descamps D
    Int J Cancer; 2011 Nov; 129(9):2147-57. PubMed ID: 21190190
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ethylene oxide exposure may increase the risk of spontaneous abortion, preterm birth, and postterm birth.
    Rowland AS; Baird DD; Shore DL; Darden B; Wilcox AJ
    Epidemiology; 1996 Jul; 7(4):363-8. PubMed ID: 8793361
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age.
    Schwarz TF; Galaj A; Spaczynski M; Wysocki J; Kaufmann AM; Poncelet S; Suryakiran PV; Folschweiller N; Thomas F; Lin L; Struyf F
    Cancer Med; 2017 Nov; 6(11):2723-2731. PubMed ID: 28984053
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.
    Moro PL; Zheteyeva Y; Lewis P; Shi J; Yue X; Museru OI; Broder K
    Vaccine; 2015 Jan; 33(4):519-22. PubMed ID: 25500173
    [TBL] [Abstract][Full Text] [Related]  

  • 65. COVID-19 vaccination in pregnancy: early experience from a single institution.
    Trostle ME; Limaye MA; Avtushka V; Lighter JL; Penfield CA; Roman AS
    Am J Obstet Gynecol MFM; 2021 Nov; 3(6):100464. PubMed ID: 34411758
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety of the HPV Bivalent and Quadrivalent Vaccines During Pregnancy.
    Forinash AB; Yancey AM; Pitlick JM; Myles TD
    Ann Pharmacother; 2011 Feb; 45(2):258-62. PubMed ID: 21285408
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.
    Garçon N; Wettendorff M; Van Mechelen M
    Expert Opin Biol Ther; 2011 May; 11(5):667-77. PubMed ID: 21457083
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
    Iversen OE; Miranda MJ; Ulied A; Soerdal T; Lazarus E; Chokephaibulkit K; Block SL; Skrivanek A; Nur Azurah AG; Fong SM; Dvorak V; Kim KH; Cestero RM; Berkovitch M; Ceyhan M; Ellison MC; Ritter MA; Yuan SS; DiNubile MJ; Saah AJ; Luxembourg A
    JAMA; 2016 Dec; 316(22):2411-2421. PubMed ID: 27893068
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes.
    Djulus J; Koren G; Einarson TR; Wilton L; Shakir S; Diav-Citrin O; Kennedy D; Voyer Lavigne S; De Santis M; Einarson A
    J Clin Psychiatry; 2006 Aug; 67(8):1280-4. PubMed ID: 16965209
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a population-based study in Taiwan.
    Huang WT; Tang FW; Yang SE; Chih YC; Chuang JH
    Vaccine; 2014 Nov; 32(48):6463-8. PubMed ID: 25285884
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immune responses elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in previously vaccinated adult women.
    Moscicki AB; Wheeler CM; Romanowski B; Hedrick J; Gall S; Ferris D; Poncelet S; Zahaf T; Moris P; Geeraerts B; Descamps D; Schuind A
    Vaccine; 2012 Dec; 31(1):234-41. PubMed ID: 23063422
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.
    Verstraeten T; Descamps D; David MP; Zahaf T; Hardt K; Izurieta P; Dubin G; Breuer T
    Vaccine; 2008 Dec; 26(51):6630-8. PubMed ID: 18845199
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach.
    Garçon N; Morel S; Didierlaurent A; Descamps D; Wettendorff M; Van Mechelen M
    BioDrugs; 2011 Aug; 25(4):217-26. PubMed ID: 21815697
    [TBL] [Abstract][Full Text] [Related]  

  • 74. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.
    Sirima SB; Richert L; Chêne A; Konate AT; Campion C; Dechavanne S; Semblat JP; Benhamouda N; Bahuaud M; Loulergue P; Ouédraogo A; Nébié I; Kabore M; Kargougou D; Barry A; Ouattara SM; Boilet V; Allais F; Roguet G; Havelange N; Lopez-Perez E; Kuppers A; Konaté E; Roussillon C; Kanté M; Belarbi L; Diarra A; Henry N; Soulama I; Ouédraogo A; Esperou H; Leroy O; Batteux F; Tartour E; Viebig NK; Thiebaut R; Launay O; Gamain B
    Lancet Infect Dis; 2020 May; 20(5):585-597. PubMed ID: 32032566
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
    Einstein MH; Levin MJ; Chatterjee A; Chakhtoura N; Takacs P; Catteau G; Dessy FJ; Moris P; Lin L; Struyf F; Dubin G;
    Hum Vaccin Immunother; 2014; 10(12):3455-65. PubMed ID: 25483700
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017.
    Landazabal CS; Moro PL; Lewis P; Omer SB
    Vaccine; 2019 Feb; 37(9):1229-1234. PubMed ID: 30660400
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pregnancy Outcomes after a Mass Vaccination Campaign with an Oral Cholera Vaccine in Guinea: A Retrospective Cohort Study.
    Grout L; Martinez-Pino I; Ciglenecki I; Keita S; Diallo AA; Traore B; Delamou D; Toure O; Nicholas S; Rusch B; Staderini N; Serafini M; Grais RF; Luquero FJ
    PLoS Negl Trop Dis; 2015 Dec; 9(12):e0004274. PubMed ID: 26713614
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
    Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
    J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
    David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
    Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Trivalent inactivated influenza vaccine and spontaneous abortion.
    Irving SA; Kieke BA; Donahue JG; Mascola MA; Baggs J; DeStefano F; Cheetham TC; Jackson LA; Naleway AL; Glanz JM; Nordin JD; Belongia EA;
    Obstet Gynecol; 2013 Jan; 121(1):159-65. PubMed ID: 23262941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.